Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)
Launched by ETABLISSEMENT PUBLIC DE SANTÉ BARTHÉLEMY DURAND · Nov 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on testing a French version of a tool called the Prediction of Alcohol Withdrawal Severity Scale (PAWSS). This tool helps doctors predict how severe a patient's alcohol withdrawal symptoms might be. The main goal of the study is to see if the French version works as well as the original English version for patients dealing with alcohol use disorders.
To participate in this study, individuals need to be between 18 and 60 years old, have a diagnosis of alcohol use disorder, and be hospitalized for alcohol withdrawal or related issues. Participants will be asked to fill out several questionnaires over a three-day hospital stay. These questionnaires will help researchers understand how their symptoms change and how well the French PAWSS works. It’s important to know that certain people, such as those who cannot understand the questions or are scheduled to leave the hospital soon, won't be eligible to join. Overall, this study aims to improve how healthcare providers assess and manage alcohol withdrawal in French-speaking patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female, aged 18 to 60 years
- • Subjects with DSM-5 criteria for alcohol use disorders (AUD)
- • Subjects hospitalized for scheduled withdrawal or patients developing alcohol withdrawal hospitalized for another reason.
- • Subjects who understand French
- • Subject affiliated to the French social security system
- • Subject having given their written consent to the study
- Exclusion Criteria:
- • Subjects transferred from other hospitalization services for whom a withdrawal syndrome could have already been treated.
- • Subjects scheduled for discharge within 48 hours.
- • Subjects with known uncontrolled epilepsy.
- • Subjects unable to understand the questionnaire.
- • Subjects unable to give consent or not volunteering for the study.
- • Subjects under guardianship or curatorship.
About Etablissement Public De Santé Barthélemy Durand
L'Établissement Public de Santé Barthélemy Durand is a prominent healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. With a focus on multidisciplinary collaboration, the establishment fosters an environment that prioritizes patient safety, ethical standards, and scientific rigor. It aims to contribute to the development of new therapeutic strategies and enhance healthcare outcomes, all while ensuring compliance with regulatory guidelines and promoting community health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
étampes, , France
Patients applied
Trial Officials
Alain Dervaux
Principal Investigator
Etablissement Public de Santé Barthélemy Durand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported